by Dr. Anna Cabeca April 01, 2017

0 Comments

09/19/2011

By Rob Goodier

NEW YORK (Reuters Health) June 21 – In older women, higher levels of endogenous estrogen at baseline predicted a lower risk of heart disease in the Women’s Health Initiative trials, a new analysis shows.

“Regardless of treatment, our hormone levels predicted your chance of heart disease,” Dr. Douglas Bauer, who led the new research at the University of California in San Francisco, told Reuters Health.  Dr. Bauer and his team presented their findings Sunday at the 93rd annual meeting of Endocrine Society in Boston.

The WHI trials studied two treatments: estrogen, and estrogen plus progestin.  The estrogen-alone trail randomized 10,739 women to take either conjugated equine estrogens, or a placebo, and tracked them for about 7 years.

The estrogen-plus-progestin trial randomized 16,608 women to take either estrogen plus medroxyprogesterone acetate, or a placebo, and tracked them for more than five years.

Overall, 748 women had heart disease events (e.g., myocardial infarction, silent MI, or cardiac death) during follow-up, including 416 subjects in the estrogen-alone trial and 332 in the estrogen-plus-progestin trial.

When Dr. Bauer and his colleagues analyzed baseline quartiles of serum estradiol (E2) levels, they found that heart disease risk decreased with higher E2 levels (p for trend, <0.05).

Futhermore, “baseline levels of total E2 did not modify the relationship between treatment and coronary heart disease risk” in either trial, the researchers said in their abstract for the meeting.

In the estrogen-plus-progestin trial, women in the highest quartile of E2 levels had a 70% lower risk of heart disease compared to those in the lowest quartile (hazard ratio: 0.3).  In the estrogen-alone trial, women with the highest E2 levels were 50% less likely to suffer a cardiac event compared to those with the lowest E2 levels (HR: 0.5).

“This is more likely to be useful in women trying to predict their risk of heart disease than in trying to determine the best treatment,” Dr. Bauer said.  “In the future, you could, perhaps, measure estrogen to tell the likelihood of heart disease.”

[fbcomments url=”http://cabecahealth.com/postmenopausal-estrogen-levels-may-predict-heart-disease/” count=”off”]

Dr. Anna Cabeca
Dr. Anna Cabeca

Dr. Anna is a Triple Board Certified OB/GYN and Anti-Aging Medicine expert who helps women heal the 9 most dreadful symptoms of menopause with natural, safe solutions. Follow her for content on hormonal imbalances, vaginal dryness, menopause (and more) that are medically backed, and created to empower women — not just treat them.



Also in Hormonal Imbalance

Estrogen Versus Androgen – Do You Know Your Body’s Secrets?
Estrogen Versus Androgen – Do You Know Your Body’s Secrets?

by Dr. Anna Cabeca May 17, 2018 0 Comments

Do you know the difference in estrogens and androgens in your body? Androgens may be more effective in supporting pelvic floor musculature and incontinence issues, as well as improving arousal and libido.
Read More
Fertility and Progesterone, a Lovely Success Story
Fertility and Progesterone, a Lovely Success Story

by Dr. Anna Cabeca May 17, 2018 0 Comments

A true story about how stress and hormone imbalances can affect a woman's fertility and how adrenal support and alkalinity can help.
Read More
Neurology Meets Gynecology: Hormones and Menopause
Neurology Meets Gynecology: Hormones and Menopause

by Dr. Anna Cabeca May 17, 2018 0 Comments

Dr. David Perlmutter interviewed me on his podcast, “The Empowering Neurologist“… about what might surprise you relating to hormones and menopause!
Read More